PF-Atlas › Clinical Trials › NCT07555106
Dapagliflozin in Living-Donor Kidney Transplant Recipients
Dapagliflozin · Phase 2
Registry ID
NCT07555106
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
Dapagliflozin (10mg Tab)
Sponsor
University of Guadalajara
Start
2024-09-15
Enrollment
54
Locations
1
About this trial
This randomized, open-label, single-center clinical trial aims to evaluate the effect of dapagliflozin on kidney allograft function in adult recipients of a first living-donor kidney transplant. Participants will be randomized to receive dapagliflozin 10 mg daily starting 4 weeks after transplantation or standard care without SGLT2 inhibitor therapy. The primary outcomes include changes in estimated glomerular filtration rate (eGFR) and albuminuria over 12 months. Secondary outcomes include kidney graft histology findings, oxidative stress biomarkers, cardiovascular parameters, infectious events, and kidney graft survival at 12 months.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT07555106 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.